Navigating a Challenging Path: Precision Disease Treatment with Tailored Oral Nano-armor-probiotics

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Date 2025 Feb 1

PMID 39893419

Authors

Anmei Chen

Ying Gong

Shaoquan Wu

Ye Du

Zhijun Liu

Yuhong Jiang

Jiahong Li

Yang-Bao Miao

Affiliations

Soon will be listed here.

Abstract

Oral probiotics have significant potential for preventing and treating many diseases. Yet, their efficacy is often hindered by challenges related to survival and colonization within the gastrointestinal tract. Nanoparticles emerge as a transformative solution, offering robust protection and enhancing the stability and bioavailability of these probiotics. This review explores the innovative application of nanoparticle-armored engineered probiotics for precise disease treatment, specifically addressing the physiological barriers associated with oral administration. A comprehensive evaluation of various nano-armor probiotics and encapsulation methods is provided, carefully analyzing their respective merits and limitations, alongside strategies to enhance probiotic survival and achieve targeted delivery and colonization within the gastrointestinal tract. Furthermore, the review explores the potential clinical applications of nano-armored probiotics in precision therapeutics, critically addressing safety and regulatory considerations, and proposing the innovative concept of 'probiotic intestinal colonization with nano armor' for brain-targeted therapies. Ultimately, this review aspires to guide the advancement of nano-armored probiotic therapies, driving progress in precision medicine and paving the way for groundbreaking treatment modalities.

References

Li M, Liu N, Zhu J, Wu Y, Niu L, Liu Y . Engineered probiotics with sustained release of interleukin-2 for the treatment of inflammatory bowel disease after oral delivery. Biomaterials. 2024; 309:122584. DOI: 10.1016/j.biomaterials.2024.122584. View

Deng B, Liu S, Wang Y, Ali B, Kong N, Xie T . Oral Nanomedicine: Challenges and Opportunities. Adv Mater. 2023; 36(6):e2306081. DOI: 10.1002/adma.202306081. View

Htwe K, Yee K, Tin M, Vandenplas Y . Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study. Am J Trop Med Hyg. 2008; 78(2):214-6. View

Mirchandani Y, Patravale V, S B . Solid lipid nanoparticles for hydrophilic drugs. J Control Release. 2021; 335:457-464. DOI: 10.1016/j.jconrel.2021.05.032. View

Prince T, McBain A, ONeill C . Lactobacillus reuteri protects epidermal keratinocytes from Staphylococcus aureus-induced cell death by competitive exclusion. Appl Environ Microbiol. 2012; 78(15):5119-26. PMC: 3416415. DOI: 10.1128/AEM.00595-12. View

Kumar D, Ashraf G, Bilgrami A, Hassan M . Emerging therapeutic developments in neurodegenerative diseases: A clinical investigation. Drug Discov Today. 2022; 27(10):103305. DOI: 10.1016/j.drudis.2022.06.005. View

Lee H, Kim N, Rheem H, Kim B, Park J, Choi I . A Decade of Advances in Single-Cell Nanocoating for Mammalian Cells. Adv Healthc Mater. 2021; 10(13):e2100347. DOI: 10.1002/adhm.202100347. View

Suda K, Matsuda K . How Microbes Affect Depression: Underlying Mechanisms via the Gut-Brain Axis and the Modulating Role of Probiotics. Int J Mol Sci. 2022; 23(3). PMC: 8835211. DOI: 10.3390/ijms23031172. View

Azad M, Sarker M, Li T, Yin J . Probiotic Species in the Modulation of Gut Microbiota: An Overview. Biomed Res Int. 2018; 2018:9478630. PMC: 5964481. DOI: 10.1155/2018/9478630. View

10.

Wang G, Wang J, Wu W, To S, Zhao H, Wang J . Advances in lipid-based drug delivery: enhancing efficiency for hydrophobic drugs. Expert Opin Drug Deliv. 2015; 12(9):1475-99. DOI: 10.1517/17425247.2015.1021681. View

11.

Shen H, Aggarwal N, Wun K, Lee Y, Hwang I, Chang M . Engineered microbial systems for advanced drug delivery. Adv Drug Deliv Rev. 2022; 187:114364. DOI: 10.1016/j.addr.2022.114364. View

12.

Haran J, McCormick B . Aging, Frailty, and the Microbiome-How Dysbiosis Influences Human Aging and Disease. Gastroenterology. 2020; 160(2):507-523. PMC: 7856216. DOI: 10.1053/j.gastro.2020.09.060. View

13.

Takeuchi T, Kameyama K, Miyauchi E, Nakanishi Y, Kanaya T, Fujii T . Fatty acid overproduction by gut commensal microbiota exacerbates obesity. Cell Metab. 2023; 35(2):361-375.e9. DOI: 10.1016/j.cmet.2022.12.013. View

14.

Bravo J, Forsythe P, Chew M, Escaravage E, Savignac H, Dinan T . Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A. 2011; 108(38):16050-5. PMC: 3179073. DOI: 10.1073/pnas.1102999108. View

15.

Mathipa-Mdakane M, Thantsha M . : A Suitable Candidate for the Construction of Novel Bioengineered Probiotic Strains for Targeted Pathogen Control. Foods. 2022; 11(6). PMC: 8947445. DOI: 10.3390/foods11060785. View

16.

Li J, Xia Q, Guo H, Fu Z, Liu Y, Lin S . Decorating Bacteria with Triple Immune Nanoactivators Generates Tumor-Resident Living Immunotherapeutics. Angew Chem Int Ed Engl. 2022; 61(27):e202202409. DOI: 10.1002/anie.202202409. View

17.

Maier L, Goemans C, Wirbel J, Kuhn M, Eberl C, Pruteanu M . Unravelling the collateral damage of antibiotics on gut bacteria. Nature. 2021; 599(7883):120-124. PMC: 7612847. DOI: 10.1038/s41586-021-03986-2. View

18.

Xie S, Zhao L, Song X, Tang M, Mo C, Li X . Doxorubicin-conjugated Escherichia coli Nissle 1917 swimmers to achieve tumor targeting and responsive drug release. J Control Release. 2017; 268:390-399. DOI: 10.1016/j.jconrel.2017.10.041. View

19.

Onoue S, Yamada S, Chan H . Nanodrugs: pharmacokinetics and safety. Int J Nanomedicine. 2014; 9:1025-37. PMC: 3934594. DOI: 10.2147/IJN.S38378. View

20.

Yadav R, Kumar V, Baweja M, Shukla P . Gene editing and genetic engineering approaches for advanced probiotics: A review. Crit Rev Food Sci Nutr. 2017; 58(10):1735-1746. DOI: 10.1080/10408398.2016.1274877. View